Summary - Funding Rounds

Founding Date

1991

Investors

Pharmacyclics is a subsidiary of AbbVie

Pharmacyclics Income Statement

Annual

USDFY, 2013FY, 2014

Revenue

260.2m729.7m

Revenue growth, %

180%

Cost of goods sold

3.5m

Gross profit

256.7m

Gross profit Margin, %

99%

R&D expense

170.9m

General and administrative expense

104.0m

Operating expense total

162.2m

EBIT

97.9m122.4m

EBIT margin, %

38%17%

Interest income

341.0k

Pre tax profit

98.1m

Income tax expense

31.1m

Net Income

67.0m86.1m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Revenue

79.1m119.4m113.0m207.1m205.8m

Cost of goods sold

6.1m9.3m11.6m16.7m

Gross profit

113.3m103.7m195.5m189.1m

Gross profit Margin, %

95%92%94%92%

R&D expense

45.1m35.3m45.7m44.0m

General and administrative expense

26.1m34.7m45.0m38.0m49.5m

Operating expense total

25.7m101.2m150.2m158.8m202.0m

Depreciation and amortization

154.0k183.0k

EBIT

53.4m18.2m(37.2m)48.4m3.8m

EBIT margin, %

68%15%(33%)23%2%

Interest income

148.0k80.0k82.0k1.0k167.0k

Pre tax profit

53.6m18.3m(37.2m)48.4m4.2m

Income tax expense

11.2m(12.0k)181.0k6.9m86.0k

Net Income

42.3m18.3m(37.1m)41.4m4.1m

Pharmacyclics Balance Sheet

Annual

USDFY, 2013FY, 2014

Cash

624.0m845.0m

Accounts Receivable

11.0m64.3m

Inventories

12.6m20.6m

Current Assets

740.8m1.0b

PP&E

25.5m32.5m

Total Assets

768.8m1.1b

Accounts Payable

4.0m7.3m

Current Liabilities

87.6m194.2m

Total Debt

Total Liabilities

141.1m

Additional Paid-in Capital

844.2m959.6m

Retained Earnings

(216.6m)(130.5m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Cash

548.4m678.6m666.3m724.5m874.7m

Accounts Receivable

53.8m27.0m45.3m53.3m77.0m

Inventories

28.7m38.3m41.4m49.0m

Current Assets

624.4m773.0m783.5m862.9m1.1b

PP&E

20.9m29.8m30.5m31.5m32.1m

Total Assets

648.3m805.8m826.1m906.6m1.1b

Accounts Payable

4.9m1.2m6.3m2.0m2.9m

Current Liabilities

67.2m95.2m130.0m144.3m194.6m

Total Liabilities

119.9m141.4m173.4m185.4m229.2m

Additional Paid-in Capital

809.2m862.7m888.1m915.2m1.0b

Retained Earnings

(280.8m)(198.3m)(235.4m)(194.0m)(126.3m)

Pharmacyclics Cash Flow

Annual

USDFY, 2013FY, 2014

Net Income

67.0m117.5m

Depreciation and Amortization

2.2m595.0k

Accounts Receivable

(11.0m)

Inventories

(12.4m)

Accounts Payable

(37.0k)1.6m

Cash From Operating Activities

88.8m110.7m

Purchases of PP&E

(18.3m)(2.4m)

Cash From Investing Activities

(20.3m)(6.4m)

Cash From Financing Activities

248.1m5.2m

Income Taxes Paid

820.0k980.0k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

42.3m18.3m(18.8m)22.6m4.1m

Depreciation and Amortization

911.0k2.0m3.2m

Accounts Receivable

(16.0m)(34.3m)(42.3m)

Inventories

(15.8m)(25.0m)(28.0m)

Accounts Payable

(2.8m)2.2m(2.0m)

Cash From Operating Activities

55.5m48.3m93.8m

Purchases of PP&E

(6.2m)(9.7m)(11.7m)

Cash From Investing Activities

(6.0m)(19.0m)(21.2m)

Cash From Financing Activities

5.2m13.0m27.9m

Pharmacyclics Employee Rating

2.3209 votes
Culture & Values
2.5
Work/Life Balance
3.0
Senior Management
2.3
Salary & Benefits
3.0
Career Opportunities
2.6
Source